Parma (Italy), September 23, 2021 – Global mobility week, which is dedicated to climate change, once again sees the return of “We ACT-Day: We Actively Care for Tomorrow”. This virtual event, organised by Chiesi in live streaming worldwide from its Parma Headquarters, involves all 30 of the Group’s affiliates. Those taking part include employees and representatives from institutions.
The term “We Act” was introduced by Chiesi in 2018 as the name for its awareness-raising program involving all its employees to promote a mindful and alternative way of acting and generate a positive impact on society and the environment.
People, patients, communities, and environment represent the cornerstones on which the Group’s strategy and actions are based, central themes of the We Act Day 2021 and its four dedicated areas: We ACT for our People, We ACT for our Community, We ACT for our Patients, We ACT to 0 Impact.
New for 2021, the theme running throughout this edition is “#EveryStoryCounts”, also the central focus of Chiesi’s last Annual & Sustainability Report, which sets out a business path aligning with the United Nations’ 2030 Agenda Sustainable Development Goals (SDGs). A path whose value has also been recognised by the Cerved Rating Agency, which has assigned Chiesi an Environmental, Social and Governance (ESG) rating of “A” based on the company’s latest Report, with an overall ESG score of 73.7 out of 100. Chiesi stands out particularly because of its environmentally friendly product innovation policy and its focus on employee wellbeing.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi changed its legal status to Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.
For further information: www.chiesi.com
Contacts for the press:
Press Office Manager
Tel: +39 339 589483,